SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-273633
Filing Date
2023-11-08
Accepted
2023-11-08 17:10:02
Documents
12
Period of Report
2023-11-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d554381d8k.htm   iXBRL 8-K 31815
  Complete submission text file 0001193125-23-273633.txt   151465

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fate-20231108.xsd EX-101.SCH 2877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20231108_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20231108_pre.xml EX-101.PRE 10830
6 EXTRACTED XBRL INSTANCE DOCUMENT d554381d8k_htm.xml XML 3271
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 231389194
SIC: 2836 Biological Products, (No Diagnostic Substances)